GB1563299A - Methods of pregnancy testing and a test kit therefor - Google Patents
Methods of pregnancy testing and a test kit therefor Download PDFInfo
- Publication number
- GB1563299A GB1563299A GB53444/76A GB5344476A GB1563299A GB 1563299 A GB1563299 A GB 1563299A GB 53444/76 A GB53444/76 A GB 53444/76A GB 5344476 A GB5344476 A GB 5344476A GB 1563299 A GB1563299 A GB 1563299A
- Authority
- GB
- United Kingdom
- Prior art keywords
- solution
- hcg
- igg
- mixture
- anti hcg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
(54) METHODS OF PREGNANCY TESTING AND
A TEST KIT THEREFOR
(71) We, RAFA LABORAT
ORIES LTD., an Israeli Company, of Ezor
Hatassya Romema, Jerusalem, Israel, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- The present invention relates to an enzymatic colour test for the determination of pree;nancy.
There are known various methods for the determination of HCG. Some biological methods require the use of specific animals, for example rabbits, mice and frogs. These biological tests have serious drawbacks; they require the availability and housing of many animals meeting specific requirements, which make the method time consuming, complicated and expensive.
There are also known some immunological tests utilising certain serodiagnostic compositions (see e.g. Israel
Patent Specifications Nos. 19301 and 34960).
There is also known a colour test utilizing antibody-enzyme-conjugates (see FEBS
Letters, Vol. 43, No. 2, July 1974, Pages 215--217).
Both the immunological and colour tests require complicated apparatus and can be performed only in an adequately equipped laboratory and with the aid of skilled people.
However, it has become desirable to develop a test which may be performed at home so that any woman can easily determine whether she is pregnant or not. It is readily understood that such test should not require any complicated means and be performable on the basis of simple instructions.
According to the first aspect of the present invention there is provided a method for the determination of pregnancy of a woman in which method an enzyme labelled anti-HCG-IgG is admixed with a sample of body fluid of the woman and preincubated: the said mixture is then admixed with insolubilized anti-HCG-IgG in the form of a gel and, after a pre-determined period of incubation, admixed with a developing dye solution, whereafter a colour change would indicate that the woman who provided the sample is pregnant.
HCG stands for human chorionic
gonadotropin and IgG for immunoglobulin
G.
As enzymes for the method according to the present invention various known enzymes may be utilised. However, the preferred ones are horse-radish peroxidase,
alkaline-phosphatase and glucose-oxidase.
The dye (solution) to be utilised is a function of the enzyme utilised. Thus, for example, for the horse-radish peroxidase, one preferably utilises o-dianisidine in a H202 solution. As another suitable dye, there should be mentioned benzidine.
Any suitable source may be utilized for obtaining the anti HCG-lgG as long as the material obtained is sufficiently specific.
Thus, for example, as suitable sources for obtaining said material one may consider rabbits and goats, as well as birds or other animals.
In a preferred embodiment of the invention one adds, in order to make the test more sensitive, one or both of the following substances:
a. normal y-globulin obtained from any suitable source-e.g. normal rabbits, sheep or goats (to help to avoid non-specific reactions).
b. some "free" anti HCG-IgG (as opposed to insolubilised) (to help to enhance the reaction), being obtained from the same sources as the gel and the enzyme labelled anti HCG-IgG. These substances, if present, are admixed first with the enzyme labelled anti HCG-lgG.
As the body-fluid there may be utilized
any fluid obtained from the woman,
preferably urine.
In a preferred embodiment of the
invention the entire mixture before being
developed by the dye solution is washed several times with a suitable washing solution (e.g.. a borate saline solution.
The test can be perfomed in any suitable transparent vessel, e.g., a test tube. even in a bag or as a paper impregnation.
If the woman is pregnant, that is HCG is present in the body fluid, a colour being specifie to the enzyme and the corresponding dye utilised appears after the addition of the developing solution. If after about half an hour after the developing solution has been added no colour appears, this an indication that the woman is not pregnant.
According to the second aspect of the present invention there is provided a kit for carrying out the method of the first aspect, which kit comprises:
(a) an enzyme labelled anti HCG-lgG: (hs meolubilized anti-HCG-IgG in the form of a gel:
(c) a developing dye solution.
In a preferred embodiment, the enzyme labelled anti HCG-lgG is used with normal g-globulin and/or free anti HCGlgG.
Ingredient (a) is preferably stored and supplied in a liophilized form.
It can readily be understood that not all said ingredients have to be packed in one box. Thus, even if one or two of the above ingredients are being packed separately this is to be considered as being within the scope of the present invention.
The present invention will now be illustrated with reference to the following
Examples without being limited by them.
Example I
Preparation of anti HCG-lgG
Normal rabbits were injected intramuscularly three limes (once a week) in the foot pad with 0.6 ml each of a suspension of HCG homogenized with an equal volume of complete Freund's adjuvant. The final concentration of HCG was 0.5 mg/ml. The potency of the HCG may vary from 28003600 u/mg and is by no means critical for the success of the iminunisation. The HCG was dissolved in a ) X5"" w/v sodium chloride solution. It may also be dissolved in any other suitable buffer solution having a pH range of 6.8-8.5.One week after the last injection the rabbits were bled and the serum separated by centrifugation, the unspecific antibodies were separated from the serum by incubation for half an hour with an equal volume of insolubilized normal human serum, and after this time the solution was centrifugated.
The specific anti llCG-lgG was precipitated from the serum by the addition of 60", (v/v) of a saturated ammonium sulphate solution (75",, w/v) to the anti HCG serum. The precipitate which was obtained was dissolved in a buffered saline solution as described and dialysed for 2-3 days against the same buffered saline solution.
The borate saline solution in this and in the following Examples was prepared as follows: I. NaCI 0.85 /" w/v
(i.e. 8.5 girl) Stock
Solution II. H3BO3 l2.37g NaOH 0.52 g
NaCI 8.00 g
H2O up to 1000 ml.
Each 97 ml of Solution I were admixed with 3 ml of Solution II.
The concentration of the anti HCG-lgG was determined by spectophotometry using w.v. at 280 my. I mglml IgG equivalent with
OD 280 my 1.4.
It is important to check that the preparation obtained is free from peroxidase activity.
EXAMPLE 2
Preparation of insolubilized anti HCG-lgG as a gel
The reaction was performed under the white light of a fluorescent lamp. After mixing 2.5 ml of a bisacrylamide solution, 2.5 ml of borate saline, 1 ml of proteins (containing 30-50 mg of anti HCG-IgG from Example I and another suitable protein source, e.g. normal rabbit IgG or
Bovine serum albumine (BSA) having a concentration of 100 mg/ml and of 0.1-0.3 ml of riboflavin (from 0.2 mg/ml aqueous solution), a photoelectric reaction occurred.
After half an hour incubation of the above mixture at 250--360C an insoluble gel appeared. The gel was homogenized and washed 3 times in borate saline. The amount
used for a test is generally from 0.1-I .0 packed gel. The bisacrylamide solution was prepared as follows:
I g of bis - (N,N' - methylbisacrylamide) (GHroN202) and
4 g of acrylamide (CH2CHCONH2) were dissolved in 19 ml of distilled water.
Example 3
Preparation of enzyme labelled anti HCG
IgG
5 mg of horseradish peroxidase were dissolved in 1.0 ml of 0.3 M sodium bicarbonate. 0.1 ml of fluorodinitrobenzene I)';, solution in absolute alcohol was added to said solution and the mixture was stirred gently for I hour. 1.0 ml of 0.06M sodium periodate was added and mixing was continued for 30 minutes. Then 1.0 ml of 0.16M ethyleneglycol was added and mixing continued. The mixture was then dialysed against a carbonate buffer (0.oil pH 9.5) for I day at 4"C. 5 mg of anti HCG-lgG were added and the mixture was mixed for 2-3 hours at room temperature.Then the mixture was dialysed against 0.01 (PBS) pH 7.1 at 4"C. The PBS was prepared by admixing:
17.5 ml Na2HPO4 0.15M 32.5 ml KH2PO4 0.15 M 50.0 ml saline (0.85% w/v
NaCI)
Approximately 90% by weight of immunoglobulin was thus labelled and 70- 90 /O by weight of peroxidase was coupled with the IgG. The labelled anti HCG-IgG was separated by passing the dialysate through a column of Sephadex G200 (Pharmacia AB). (The word "Sephadex" is a Trade Mark). The enzyme labelled anti HCG-lgG may be stored in a freeze dried form in a concentration suitable for one or more tests.The enzyme activity is measured in a spectrophotometer, visible light, wavelength 460 m,u. (0.1 ml test mixture, 2.9 ml dye incubated for 3 min. at room temperature). I drop of HCI 6N was added to stop the reaction and the result read in the spectrophotometer. The enzyme activity is expressed in mU and it is calculated as follows:
A/min.
1 mU= 103
3.766
A=OD absorption
EXAMPLE 4
Performance of the test
The following reagents are mixed in a test tube and are pre-incubated for A hour.
a. 0.1 ml of an enzyme labelled anti HCGlgG having an enzyme activity of 65 my.
b. 0.1 ml of normal rabbit y-globulin (or sheep or goat) having a concentration of 10--100 mg/ml.
c. 0.1 ml of body fluid to be tested, preferably urine.
The addition of 0.1 mg-0.5 mg of free
HCG-lgG enables the reaction to be more sensitive.
After the pre-incubation period the mixture was passed into another tube containing the packed insolubilized anti HCG-IgG gel in a volume of about 0.3 ml. This composition was left for an incubation period of 15-30 minutes. After this time, the composition was washed four times with borate saline (by centrifugation or by immersion of a nylon bag containing the mixture in the solution). After the last washing, 2.5 ml of the developing dye solution (prepared as described herein) are added, the composition is shaken well and left to stand for about 5 minutes. If HCG was present in the test body fluid, a reddish brown colour will appear; if not, a reddish brown colour will not appear.
Preparation of the dye solution
0.5 ml of a 0.3 "v/v H202 solution was put into a 0.01 M phosphate buffer having pH 6 up to a volume of 50 ml. 0.41 ml of a 1 " w/v orthodianisidine aqueous solution was then added to the above buffered solution.
WHAT WE CLAIM IS:
1. A method for the determination of pregnancy of a woman, in which method an
enzyme labelled anti HCG-lgG is admixed with a sample of body fluid of the woman:
and pre-incubated; the mixture is then
admixed with insolubilized anti HCG-IgG in the form of a gel and, after a predetermined
period of incubation, admixed with a
developing dye solution, whereafter a
colour change would indicate that the woman who provided the sample is pregnant.
2. A method according to Claim 1, wherein the enzyme utilized is horse-radish peroxidase.
3. A method according to Claim 1 or 2, in which the dye solution is o-dianisidine in an H202 solution.
4. A method according to any one of
Claims 1 to 3, in which the enzyme labelled
anti HCG-IgG is first admixed with normal
y-globulin and/or free anti HCG-IgG.
5. A method according to any one of
Claims 1 to 4, wherein the body fluid utilised is urine.
6. A method according to any one of
Claims 1 to 5, wherein the mixture is washed before the dye solution is admixed therewith.
7. A method according to claim 6, wherein the washing solution is a borate saline solution.
8. A method for the determination of pregnancy, substantially as hereinbefore described with reference to the Examples.
9. A test kit for carrying out the method according to any of Claims I to 8, which kit comprises:- (a) an enzyme labelled anti HCG-IgG;
(b) insolubilized anti HCG-IgG in the form of a gel;
(c) a developing dye solution.
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (13)
1. A method for the determination of pregnancy of a woman, in which method an
enzyme labelled anti HCG-lgG is admixed with a sample of body fluid of the woman:
and pre-incubated; the mixture is then
admixed with insolubilized anti HCG-IgG in the form of a gel and, after a predetermined
period of incubation, admixed with a
developing dye solution, whereafter a
colour change would indicate that the woman who provided the sample is pregnant.
2. A method according to Claim 1, wherein the enzyme utilized is horse-radish peroxidase.
3. A method according to Claim 1 or 2, in which the dye solution is o-dianisidine in an H202 solution.
4. A method according to any one of
Claims 1 to 3, in which the enzyme labelled
anti HCG-IgG is first admixed with normal
y-globulin and/or free anti HCG-IgG.
5. A method according to any one of
Claims 1 to 4, wherein the body fluid utilised is urine.
6. A method according to any one of
Claims 1 to 5, wherein the mixture is washed before the dye solution is admixed therewith.
7. A method according to claim 6, wherein the washing solution is a borate saline solution.
8. A method for the determination of pregnancy, substantially as hereinbefore described with reference to the Examples.
9. A test kit for carrying out the method according to any of Claims I to 8, which kit comprises:- (a) an enzyme labelled anti HCG-IgG;
(b) insolubilized anti HCG-IgG in the form of a gel;
(c) a developing dye solution.
10. A kit according to Claim 9, wherein
the enzyme labelled anti HCG-IgG is admixed with normal y-globulin and/or free anti HCG-lgG.
II. A kit according to Claim 9 or 10, wherein ingredient (a) is in a liophilized form.
12. A method of pregnancy testing,
substantially as described in foregoing
Example 4.
13. A kit for the performance of
pregnancy testing, substantially as described
in foregoing Example 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL48741A IL48741A (en) | 1975-12-26 | 1975-12-26 | Method for the determination of pregnancy |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1563299A true GB1563299A (en) | 1980-03-26 |
Family
ID=11048617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB53444/76A Expired GB1563299A (en) | 1975-12-26 | 1976-12-21 | Methods of pregnancy testing and a test kit therefor |
Country Status (14)
Country | Link |
---|---|
JP (1) | JPS5282892A (en) |
AT (1) | AT352904B (en) |
AU (1) | AU2049576A (en) |
BE (1) | BE849667A (en) |
DE (1) | DE2657292A1 (en) |
ES (1) | ES454542A1 (en) |
FI (1) | FI763647A (en) |
FR (1) | FR2336113A1 (en) |
GB (1) | GB1563299A (en) |
IL (1) | IL48741A (en) |
IT (1) | IT1068738B (en) |
NL (1) | NL7614359A (en) |
SE (1) | SE7614387L (en) |
ZA (1) | ZA767607B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0062892A1 (en) * | 1981-04-13 | 1982-10-20 | American Hoechst Corporation | Single incubation immunochemical assay for creatin phosphokinase MB |
EP0074520A1 (en) * | 1981-09-16 | 1983-03-23 | Teva Pharmaceutical Industries Limited | Method and kit for pregnancy detection |
US4419453A (en) | 1981-09-28 | 1983-12-06 | The Dow Chemical Company | Immunological agglutination assays with dyed or colored latex and kits |
US4543339A (en) * | 1982-03-16 | 1985-09-24 | Oneill Christopher | Early pregnancy detection by detecting enhanced blood platelet activation |
WO1986005498A1 (en) * | 1985-03-12 | 1986-09-25 | University Of Queensland | Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody |
EP0210863A1 (en) * | 1985-07-29 | 1987-02-04 | Modern Diagnostics, Inc. | Immunoassay |
DE3590722T1 (en) * | 1982-08-20 | 1987-11-19 | ||
US7034120B2 (en) | 1999-02-02 | 2006-04-25 | Edp Biotech Corporation, Inc. | Method and apparatus for detecting conception in animals |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1337394C (en) * | 1987-11-17 | 1995-10-24 | Nelson N. H. Teng | Vaginal sample test and reagents |
-
1975
- 1975-12-26 IL IL48741A patent/IL48741A/en unknown
-
1976
- 1976-12-13 AU AU20495/76A patent/AU2049576A/en not_active Expired
- 1976-12-15 JP JP15067576A patent/JPS5282892A/en active Pending
- 1976-12-17 DE DE19762657292 patent/DE2657292A1/en active Pending
- 1976-12-20 FR FR7638333A patent/FR2336113A1/en not_active Withdrawn
- 1976-12-20 FI FI763647A patent/FI763647A/fi not_active Application Discontinuation
- 1976-12-21 SE SE7614387A patent/SE7614387L/en unknown
- 1976-12-21 IT IT70054/76A patent/IT1068738B/en active
- 1976-12-21 GB GB53444/76A patent/GB1563299A/en not_active Expired
- 1976-12-21 BE BE173475A patent/BE849667A/en unknown
- 1976-12-22 ZA ZA767607A patent/ZA767607B/en unknown
- 1976-12-23 ES ES454542A patent/ES454542A1/en not_active Expired
- 1976-12-23 AT AT962176A patent/AT352904B/en not_active IP Right Cessation
- 1976-12-23 NL NL7614359A patent/NL7614359A/en not_active Application Discontinuation
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0062892A1 (en) * | 1981-04-13 | 1982-10-20 | American Hoechst Corporation | Single incubation immunochemical assay for creatin phosphokinase MB |
EP0074520A1 (en) * | 1981-09-16 | 1983-03-23 | Teva Pharmaceutical Industries Limited | Method and kit for pregnancy detection |
US4419453A (en) | 1981-09-28 | 1983-12-06 | The Dow Chemical Company | Immunological agglutination assays with dyed or colored latex and kits |
US4543339A (en) * | 1982-03-16 | 1985-09-24 | Oneill Christopher | Early pregnancy detection by detecting enhanced blood platelet activation |
DE3590722T1 (en) * | 1982-08-20 | 1987-11-19 | ||
WO1986005498A1 (en) * | 1985-03-12 | 1986-09-25 | University Of Queensland | Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody |
GB2192634B (en) * | 1985-03-12 | 1990-03-21 | Univ Queensland | Method of detecting early pregnancy factor (epf) in mammals, purifying epf and method for providing a monoclonal antibody |
EP0210863A1 (en) * | 1985-07-29 | 1987-02-04 | Modern Diagnostics, Inc. | Immunoassay |
US7179640B2 (en) | 1998-02-02 | 2007-02-20 | Edp Biotech Corporation | Method and apparatus for detecting conception in animals |
US7034120B2 (en) | 1999-02-02 | 2006-04-25 | Edp Biotech Corporation, Inc. | Method and apparatus for detecting conception in animals |
Also Published As
Publication number | Publication date |
---|---|
ATA962176A (en) | 1979-03-15 |
BE849667A (en) | 1977-06-21 |
NL7614359A (en) | 1977-06-28 |
IL48741A (en) | 1979-07-25 |
IL48741A0 (en) | 1976-02-29 |
DE2657292A1 (en) | 1977-07-14 |
AU2049576A (en) | 1978-06-22 |
ES454542A1 (en) | 1978-04-01 |
ZA767607B (en) | 1977-11-30 |
FR2336113A1 (en) | 1977-07-22 |
IT1068738B (en) | 1985-03-21 |
JPS5282892A (en) | 1977-07-11 |
FI763647A (en) | 1977-06-27 |
AT352904B (en) | 1979-10-10 |
SE7614387L (en) | 1977-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gaither et al. | Studies of the molecular mechanisms of C3b inactivation and a simplified assay of β1H and the C3b inactivator (C3bINA) | |
US4732863A (en) | PEG-modified antibody with reduced affinity for cell surface Fc receptors | |
Saboori et al. | Iodination of human thyroglobulin (Tg) alters its immunoreactivity. I. Iodination alters multiple epitopes of human Tg | |
Schwartz et al. | Comparisons of rat cardiac myosins at fetal stages in young animals and in hypothyroid adults. | |
Ruddy et al. | Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein | |
Kolk et al. | Isolation, chemical and immunological characterization of two strongly basic nuclear proteins from human spermatozoa | |
Hoffman | Allergens in bee venom: III. Identification of allergen B of bee venom as an acid phosphatase | |
Petts et al. | Peroxidase conjugates for demonstration of tissue antibodies: evaluation of the technique | |
CN104792997B (en) | A kind of HCT's original immunity detection reagent and preparation method and application | |
GB1563299A (en) | Methods of pregnancy testing and a test kit therefor | |
ATE244299T1 (en) | TESTING AND TREATING DEMYELINATING DISEASES SUCH AS MULTIPLE SCLEROSIS | |
Barral-Netto et al. | Enzyme-linked immunosorbent assay for the detection of Bothrops jararaca venom | |
Aitkaci et al. | Enzyme-linked immunosorbent assay for anti-histone antibodies and their presence in systemic lupus erythematosus sera | |
Irabuena et al. | Characterization and optimization of bovine Echinococcus granulosus cyst fluid to be used in immunodiagnosis of hydatid disease by ELISA | |
Musmand et al. | Identification of important allergens in German cockroach extracts by sodium dodecylsulfate–polyacrylamide gel electrophoresis and Western blot analysis | |
Kulmacz et al. | Topographic studies of microsomal and pure prostaglandin H synthase | |
Gröschel-Stewart et al. | Immunological evidence for human myosin isoenzymes | |
BR9710175A (en) | Methods to determine the presence of the brain s-100 protein. | |
Piazolo et al. | Calcium-binding protein in the duodenal mucosa of uremic patients and normal subjects | |
Jackson et al. | Antigenic properties of soluble elastins and their use in detecting soluble elastin in ligament extracts | |
Kurki | Determination of anti-actin antibodies by a solid-phase immunoenzymatic assay and by indirect immunofluorescence technique | |
Warren et al. | Characterization of the renin-antirenin system | |
Baudner | Analysis of plant proteins using immunological techniques based on the antigen-antibody precipitation | |
Richie et al. | A New Serum Factor in Normal Rabbits: VI. Reaction with Buried Determinants of IgG Exposed Sequentially with CNBr, Pepsin and Papain | |
Eitenmiller et al. | Immunochemical studies on human and bovine milk lysozymes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CSNS | Application of which complete specification have been accepted and published, but patent is not sealed |